Search results
Moderna director Noubar Afeyan sells shares worth over $2.9 million By Investing.com
Investing.com· 11 hours agoModerna , Inc. (NASDAQ:MRNA) director Noubar Afeyan has sold a total of $2,901,584 worth of company...
Moderna Wins Second-Ever Approval. But It Could Dominate Pfizer, GSK.
Investor's Business Daily· 18 hours agoLike rivals Pfizer (PFE) and GSK (GSK) — which gained their approvals and launched last year — ...
FDA approves Moderna’s mRNA RSV vaccine for older adults – KION546
KION 46 Salinas· 15 hours agoThe shot, made by Moderna and sold under the name of mResvia, could be another tool in the country’s...
Moderna's RSV vaccine for older adults approved
Axios· 14 hours agoModerna's RSV shot for adults 60 and older was approved by the Food and Drug Administration on Friday, joining a growing group of vaccines protecting...
Is Moderna Stock A Buy As The U.S. Government Mulls Its Bird Flu Vaccine?
Investor's Business Daily· 21 hours agoModerna confirmed it's in discussions with the U.S. government to move forward with its bird flu...
Moderna’s stock climbs on report that bird-flu vaccine funding is near
Market Watch· 2 days agoModerna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a...
US FDA approves Moderna's RSV vaccine with lower-than-expected efficacy in its label
Reuters· 12 hours ago, opens new tab respiratory syncytial virus (RSV) vaccine, the company announced on Friday, giving...
FDA approves Moderna’s mRNA RSV vaccine
The Hill via Yahoo News· 19 hours agoThe Food and Drug Administration (FDA) has approved Moderna’s RSV mRNA vaccine for adults older than 60 years. The approval makes RSV the second disease...
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
Benzinga via Yahoo Finance· 15 hours agoOn Friday, the FDA approved Moderna Inc’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory...
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 23 hours agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.